Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/19/17
End: 06/21/18
Due: 06/21/19
Phase: N/A
Priority: Normal
Start: 08/08/22
End: 03/23/23
Due: 03/23/24
Phase: N/A
Priority: Normal
Start: 11/08/24
End: 04/30/25
Due: 04/30/26
Phase: N/A
Priority: Normal
Start: 11/01/21
End: 12/31/22
Due: 12/31/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Blueberry Consumption and Type 2 Diabetes | NCT02972996 | Albany Research Institute, Inc. | user2@example.com | None | 2017-01-19 | 2018-06-21 | 2019-06-21 | - | - | 2025-07-14 |
| Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD | NCT05895318 | Albany Research Institute, Inc. | user2@example.com | None | 2022-08-08 | 2023-03-23 | 2024-03-23 | - | - | 2025-07-14 |
| Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-Life | NCT06824532 | Albany Research Institute, Inc. | user2@example.com | None | 2024-11-08 | 2025-04-30 | 2026-04-30 | - | - | 2025-07-14 |
| Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea | NCT05616923 | Albany Research Institute, Inc. | user2@example.com | None | 2021-11-01 | 2022-12-31 | 2023-12-31 | - | - | 2025-07-14 |